Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab
Gains Rights To Perjeta And Prolia/Xgeva Biosimilars As Well As Ipilimumab Option
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.
You may also be interested in...
With Organon’s Humira biosimilar Hadlima reaching the US market earlier this month, the company’s biosimilars commercial lead in the market, Jon Martin, spoke to Generics Bulletin about the seminal event, as well as the company’s commercialization-only business model.
Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.
With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.